Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Researchers Identify First Mutation to Explain Resistance to Venetoclax

TON - February 2019, Vol 12, No 1 - Leukemia
Phoebe Starr

San Diego, CA—The BCL2 Gly101Val mutation is the first genomic alteration to be identified as responsible for resistance to venetoclax (Venclexta), a potent and effective medication indicated for the treatment of chronic lymphocytic leukemia (CLL). The BCL2 Gly101Val mutation is unique to CLL and so far has not been described in other cancers.

“Despite the effectiveness of venetoclax, a majority of patients will relapse. Up until now, we had no idea why. The discovery of a genetic mutation that confers resistance to venetoclax offers an explanation of why venetoclax stops working in some patients,” said lead investigator Piers Blombery, MBBS, Consultant Haematologist, Peter MacCallum Cancer Centre, Melbourne, Australia.

“We have shown that in some cases the mutation can be detected in patients’ bone marrow years before clinical signs of relapse appear,” Dr Blombery told listeners at ASH 2018.

“The molecular basis of venetoclax resistance is largely unknown for patients with CLL who progress and for those who go on to Richter’s transformation,” Dr Blombery continued.

Acquired Resistance Mutation

The study was based on 67 patients with relapsed CLL who received treatment with venetoclax in 3 early clinical trials: 21 with CLL-like progression, 18 with Richter’s transformation, and 28 with no disease progression.

Of the 21 patients with CLL progression, 15 had samples suitable for genetic analysis with next-generation sequencing (NGS) on a panel of 33 genes; NGS was done before patients started treatment with venetoclax and when resistance developed.

BCL2 Gly101Val was identified in 4 patients with CLL progression while receiving venetoclax, but it was absent in samples from these 4 patients before starting venetoclax therapy, demonstrating that it is an acquired mutation associated with venetoclax.

BCL2 Gly101Val was not found in samples from over 400 patients with other hematologic malignancies. We also didn’t find it in any CLL patient not exposed to venetoclax. It is associated with a 180-fold decrease in the affinity to bind to the BCL2 protein,” Dr Blombery explained. “Of note, BCL2 Gly101Val is subclonal; that is, it is detectable in patients before overt clinical relapse,” he added.

“The mutation appears after at least 20 months of venetoclax therapy, so it is a late mutation. Wherever it was detectable, the patient progressed to clinical relapse,” he continued.

Additional Mutations Identified

BCL2 Gly101Val is not the only mutation that contributes to resistance. BCL2 Gly101Val was present in 75% of cells, but 25% were not driven by this mutation, and other mutations were identified in those cells.

“The fact that BCL2 Gly101Val is subclonal implicates multiple mechanisms of venetoclax resistance in the same patient,” Dr Blombery said.

“This provides a strong rationale for time-limited venetoclax, which several researchers are exploring. When you give patients a highly selective targeted agent like venetoclax, it doesn’t take long for resistance to develop. The mutation popped up before 2 years of therapy, so we think that is a reasonable time to stop the venetoclax,” Dr Blombery stated.

“Patients can be screened for BCL2 Gly101Val while on venetoclax. If the mutation is detected, it would be prudent for the hematologist to begin to think about other therapies to use,” Dr Blombery commented.

“Perhaps a more aggressive combination therapy should be used. This disease has multiple genomic tricks up its sleeve,” he told listeners.

Related Items
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TON - October 2019, Vol 12, No 5 published on October 7, 2019 in Geriatric Cancer
Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities
Phoebe Starr
TON - October 2019, Vol 12, No 5 published on October 7, 2019 in Leukemia
MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Breast Cancer
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ASCO
Osimertinib plus Savolitinib Promising for Non–Small-Cell Lung Cancer with MET-Driven Resistance
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Lung Cancer
High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Lung Cancer
Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Leukemia
Infigratinib a Novel, Potent Selective TKI Targeting FGFR Fusions in Different Tumor Types
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Emerging Therapies
Umbralisib Shows Encouraging Results in Relapsed or Refractory Marginal-Zone Lymphoma
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Lymphoma
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Leukemia
Last modified: August 6, 2019